Tag: labs

DELRAY BEACH, Fla., June 12, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the In Vitro Toxicology Testing Market is projected to grow from about USD...

The Twist Fast Hyb App joins Twist's Standard Hyb v2 App on Callisto, giving labs a fully walk-away path to target enrichment, with run-to-run...

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR...

The Twist Fast Hyb App joins Twist's Standard Hyb v2 App on Callisto, giving labs a fully walk-away path to target enrichment, with run-to-run...

The Emerging Techbio Company Appoints Dr. John Mumm as CSO Alongside Head of Platform Dr. Yambazi Banda to Decode the Molecular Underpinnings of Neuroimmune...

Ingredion names Kenneth Escoe to its Board, adding global operations, M&A and industrial leadership expertise to support long-term growth.

Biohub and UC Berkeley show that the laser phase plate, a revolutionary device with a laser 100 million times brighter than the Sun, dramatically...

BANGALORE, India, June 11, 2026 /PRNewswire/ --  ...

Live, Boot Camp-Style Training Now Available to Federal, State and Local Government AgenciesPLANO, Texas and RESTON, Va., June 10, 2026 /PRNewswire/ -- Simplilearn, a...

Live, Boot Camp-Style Training Now Available to Federal, State and Local Government AgenciesPLANO, Texas and RESTON, Va., June 10, 2026 /PRNewswire/ -- Simplilearn, a...

Case Series by Dr. Robert Parker, DPM, Published in Archives of Clinical...

AUSTIN, Texas and DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced the pricing of its previously announced a public offering of 10,879,376 shares of its common stock at a public offering price per share of $4.00 and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 7,870,624 shares of its common stock at a public offering price of $3.9999 per pre-funded warrant. The pre-funded warrants have an exercise price of $0.0001 per share and are exercisable immediately. The aggregate gross proceeds to Shattuck from the offering are expected to be approximately $75 million before deducting underwriting discounts and commissions and other offering expenses payable by Shattuck, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on June 11, 2026, subject to the satisfaction of customary closing conditions. In addition, Shattuck has granted the underwriters an option for a period of 30 days to purchase up to an additional 2,812,500 shares of its common stock at the public offering price, less underwriting discounts and commissions.